NEW YORK (
) --
(Nasdaq:
) hit a new 52-week high Wednesday as it is currently trading at $42.50, above its previous 52-week high of $42.39 with 737,797 shares traded as of 3:15 p.m. ET. Average volume has been 798,900 shares over the past 30 days.
Cubist has a market cap of $2.41 billion and is part of the
sector and
industry. Shares are up 5.6% year to date as of the close of trading on Tuesday.
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company has a P/E ratio of 15.5, below the average drugs industry P/E ratio of 75.2 and below the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Cubist as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. You can view the full
.
See all
52-week high stocks
or get investment ideas from our
.
null
